Increased intracranial pressure (ICP) secondary to severe brain injury is common. Increased ICP is commonly encountered in malignant middle cerebral artery ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage. Multiple interventions-both medical and surgical-exist to manage increased ICP. Medical management is used as first-line therapy; however, it is not always effective and is associated with significant risks. Decompressive hemicraniectomy is a surgical option to reduce ICP, increase cerebral compliance, and increase cerebral blood perfusion when medical management becomes insufficient. The purpose of this review is to provide an up-to-date summary of the use of decompressive hemicraniectomy for the management of refractory elevated ICP in malignant middle cerebral artery ischemic stroke, traumatic brain injury, subarachnoid hemorrhage, and intracerebral hemorrhage.
Introduction
Increased intracranial pressure (ICP) secondary to cerebral edema is common in acute neurological disorders. Severe edema can be seen in malignant middle cerebral artery (MCA) ischemic stroke, traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH). Increased ICP can lead to life-threatening herniation syndromes and is a common cause of death when left untreated.
Decompressive hemicraniectomy (DHC) is a surgical option to reduce ICP, increase cerebral compliance, and increase cerebral blood perfusion when medical management becomes insufficient. The typical DHC performed is via a unilateral approach to remove a 12-to 14-cm bone flap. By removing the skull, the brain is allowed to expand, thereby normalizing ICP and reducing compression and/or midline shift. By reducing ICP, cerebral perfusion pressure and blood flow are restored.
This article will summarize current medical literature regarding DHC in ICHs, SAH, malignant MCA stroke, and TBI.
Decompressive Hemicraniectomy in the Setting of ICH Current guidelines for the management of spontaneous ICH developed by the American Heart Association and American Stroke Association (AHA/ASA) recommend initial medical therapy and external ventricular drainage for elevated ICP. 1 The guidelines also address surgical management but not for treatment of refractory elevated ICP.
No large randomized trials have evaluated the use of DHC in ICH. There have only been a few case/control and case series regarding DHC for the management of refractory ICP in ICH, and these studies are divided between DHC alone and hematoma evacuation in combination with DHC. [2] [3] [4] [5] [6] [7] [8] [9] Table 1 provides a summary of the studies describing DHC in patients with ICH. more than half had a GCS of 9 to 12. Seven patients had an ICH volume of greater than 60 cm 3 , whereas 13 had a volume between 30 and 60 cm 3 . The majority of patients had surgery performed within 6 hours of presentation, but no details regarding exact timing were provided. Mortality rate was low in this case series (13%), but this finding may be partly explained by the low severity of illness with a relatively high GCS and small hematoma volumes. Intracerebral hemorrhage score was not reported, which would have allowed for better comparison with other studies.
Fung et al 8 performed a case-control study of 12 patients. These patients had a larger median hematoma volume of 61 cm 3 compared to the study by Ramnarayan et al. 4 Median time to DHC was within 12 hours with a mortality rate of 25% in the DHC group, whereas the controls had a 53% mortality rate. Furthermore, mortality was increased with conservative management compared to surgical management if the volume of the ICH was greater than 60 cm 3 .
Decompressive Hemicraniectomy With Hematoma Evacuation
The oldest and largest reported series of patients with hematoma evacuation along with DHC is a 73-patient case-control series by Dierssen et al 9 in 1983. Glasgow Coma Scale was not directly reported on admission, but 43 (59%) patients presented with a neurological examination of stupor to deep coma. Despite having a poor initial presentation, the long-term functional outcome was good in nearly half of the survivors and they found an improvement in mortality after craniectomy. Murthy et al 5 published a 12-patient cases series in which the majority of the patients (92%) survived to follow-up at 17 months, and good functional outcome was achieved in 55% of the patients (modified Rankin Scale [mRS]: 0-3). Good functional outcome would have increased to 67% if it was defined as an mRS of 0 to 4. The conclusions from this study should be limited, with its small sample size. Moreover, there may have been a selection bias as 92% of the patients had right hemispheric pathology. Kim et al 7 described 24 patients, 19 (79%) of whom had a GCS less than 8. Good functional outcome was defined as a Glasgow Outcome Scale (GOS) of 4 to 5 and was present in half the patients at 6 months. A majority of patients had poor neurological examinations, but the authors did not provide enough of their data to analyze the utility of DHC in their patient population. Also, indications for surgery in this study (GCS < 8) may have caused delays for patients who would have benefited from earlier decompression.
Ma et al 6 performed a case-control study of 38 patients. Controls were patients who received a hematoma evacuation alone. In unadjusted analysis, there was a 32% mortality rate in the DHC group compared to 43% in the control group (P ¼ .26). There were significantly more patients with herniation, patients with intraventricular hemorrhage, and patients with a higher ICH score in the DHC group than the control group. The patients' ICH score, hematoma volumes, and admission GCS 
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Journal of Intensive Care Medicine 31 (9) may have played a role in the higher mortality rates than other studies in our review. When adjusted for these variables, the odds ratio for 30-day mortality was 0.12 (95% confidence interval [CI]: 0.02-0.64, P ¼ .01), and an adjusted odds ratio for good outcome (GOS: 3-5) was 23.23 (95% CI: 2.13-252.86, P ¼ .01). Takeuchi et al 2 described patients with a median ICH score of 3. All patients were taken for surgery within 24 hours of presentation. Patients had lower GCS scores, higher ICH volumes, and longer delay prior to surgery when compared to other published studies, which may explain the worse outcomes.
Conclusions
Bearing in mind the differences in methodology between all 7 studies, there was an overall combined mortality of 26%. It is fair to conclude that DHC done alone or combined with hematoma evacuation appears to be safe. Patients in both populations demonstrated that this surgical technique may reduce mortality, as well as improve functional outcome, especially in those who have large hematoma volume, low GCS score, and high ICH score.
Further prospective randomized trials are warranted, but given the above studies, we recommend that patients with refractory ICP elevation in the setting of ICH should undergo DHC with or without hematoma evacuation depending on individual characteristics. Patients who seem to benefit the most are those with poor neurological examinations and large hematoma volumes.
Decompressive Hemicraniectomy in the Setting of Aneurysmal SAH
Decompressive hemicraniectomy has been performed for the management of refractory elevated ICP in patients suffering from aneurysmal SAH. The current literature consists of single-institution case series and a single case-control study. Table 2 provides a summary of the key studies that have been published thus far. The largest study done by Dorfer et al 10 stratified patients into 4 different groups for their analysis. Group 1 consisted of patients undergoing aneurysm clipping and DHC during the initial procedure (ie, primary DHC). Group 2 consisted of patients undergoing DHC who had endovascular treatment of their ruptured aneurysm and developed intractable intracranial hypertension immediately or in a delayed fashion. Group 3 consisted of patients who had DHC done after initial clipping of aneurysm but in a delayed fashion. Group 4 consisted of patients in group 1 who required repeat surgery to enlarge the primary DHC. The authors found no significant difference in neurological outcome based on the group the patient was assigned. Interestingly, the authors did not find that timing of DHC influenced functional outcome. The main finding of their study was that etiology of intractable ICP influenced functional outcome. Patients undergoing DHC secondary to a hematoma had improved functional outcome (P ¼ .038) compared to patients undergoing DHC due to cerebral edema secondary to ischemic infarction. The weakness of the study is the lack of a comparison group and its retrospective design.
In contrast, Buschmann et al 11 also grouped patients based on the indication for DHC and showed that timing of DHC could potentially be a factor affecting long-term functional outcome. Patients in group 1 had primary DHC; group 2 were patients who developed intractable ICP (>20 mm Hg) and space occupying epidural, subdural, or intracerebral hematoma after aneurysm surgery (secondary DHC due to hematoma); group 3 consisted of patients who developed cerebral edema and intractable ICP without infarctions (secondary DHC without infarctions); and group 4 had elevated ICP and infarctions (secondary DHC with infarctions). Notably, the majority of the patients in their study were in group 1 (55%). Patients who recovered with good functional outcome (GOS: 4 and 5) were treated earlier by secondary DHC (within 3.6 + 1.6 days after SAH) than those who died or survived with severe or moderate disability (GOS: 1-3) who were treated later (within 5.9 + 5.5 days; P ¼ .12). Also in this study, the outcome of the patients differed according to the indication for DHC with 83.3% of patients in group 3 (secondary DHC without infarctions) having a good functional outcome. However, there were only 6 patients in this group.
Nonetheless, the study by D'Ambrosio et al 12 came to a different conclusion. In this study of patients with poor-grade SAH presenting with focal ICH necessitating DHC, quality of life (QoL) was assessed in addition to functional outcome. Patients who underwent DHC did not have improved QoL or functional outcome compared to a similar group of patients treated conservatively. A methodological weakness is that the control group used had smaller hematoma volume, less midline shift, and higher GCS. Furthermore, although the average time to hemicraniectomy for the group as a whole was only 11.4 (+4.3) hours, half the patients had DHC performed greater than 24 hours after onset of clinical signs of brainstem compression. Despite the negative findings of this study, 33% of patients in the DHC group had a good functional outcome at 1 year.
A similar study was conducted by Smith et al 15 also in a population of patients with poor-grade SAH presenting with a focal ICH (sylvian fissure hematoma greater than 25 mL ipsilateral to an MCA aneurysm). However, unlike the study done by D'Ambrosio et al, 12 the patients in this study all had a prophylactic DHC, which was planned from the outset of the aneurysm clipping operation. This earlier time frame for the performance of the DHC may explain the significantly different results, which showed that 62% of the patients had good functional outcome at 1 year. Unfortunately, the authors do not report the actual timing of the DHC in relation to the onset of SAH. In this study, DHC led to a significant and sustained decrease in elevated ICP and the procedure added only 20 to 25 minutes to the original operation.
In contrast to the 2 previous studies, Schirmer et al 13 evaluated patients presenting with SAH with small-to-no ICH. Notably, in this small study, half of the patients had their aneurysm treated via endovascular coiling. This study supports the theory that early DHC may be more beneficial than delayed DHC. The authors noted that DHC performed within the first 48 hours after SAH had a beneficial effect on outcome: 75% of the patients who underwent early DHC fared better at long-term follow-up (mRS: 0-3) compared to 12.5% of patients in whom DHC was performed after 48 hours (P < .01). The strength of this study is that herniated brain volume was assessed, however, the authors do not describe in detail what is meant by maximal medical management, which was an inclusion criterion. Lastly, Guresir et al 14 evaluated the outcome of patients undergoing primary or secondary DHC for the management of refractory elevated ICP stratified according to the different underlying pathologies in order to determine predictors to help guide treatment. Patients were stratified as follows: group 1 (primary DHC) had craniectomy enlarged after aneurysm clipping in the presence of massive brain swelling, group 2 had craniectomy enlarged after aneurysm clipping in the presence of massive brain swelling with additional ICH, group 3 had intractable ICP without radiological signs of rebleeding or infarction, group 4 had intractable ICP with signs of infarction, and group 5 had intractable ICP with rebleeding. They found that the outcome was comparable regardless of the underlying etiology leading to DHC. The weakness of the study is the small number of patients in groups 1, 3, and 5.
One of the challenges particular to the management of patients with SAH is the development of delayed cerebral ischemia. In a patient afflicted by ICH associated with SAH, the timing of peak perihematomal edema formation coincides with the beginning of the development of vasospasm. Therefore, a dilemma may occur in which deterioration in a patient's neurological examination is difficult to distinguish whether it is due to delayed cerebral ischemia, elevated ICP, or both. It is clear that DHC leads to effective and sustained ICP control, thus helping to address this clinical dilemma. If a patient has significant improvement after DHC is performed, it can be inferred that the underlying pathophysiology was elevated ICP and not delayed cerebral ischemia. More importantly perhaps is that the treatment of elevated ICP and vasospasm use conflicting strategies. The use of hyperventilation and hyperosmolar therapy, for instance, could lead to increased vasoconstriction and dehydration, respectively, both potentially worsening delayed cerebral ischemia. Decompressive hemicraniectomy in patients with SAH allows the clinician to treat delayed cerebral ischemia effectively without concern for exacerbating elevated ICP from induced hypertension or hypervolemia.
Furthermore, patients with SAH may have various underlying etiologies leading to elevated ICP including ICH, infarction, rebleeding, and cerebral edema. Several studies 10, 11, 15 suggest that the underlying etiology leading to elevated ICP could play a role in determining the effectiveness of DHC. These studies suggest that performing DHC for intractable ICP in the setting of an ICH associated with SAH is beneficial. However, Guresir et al 14 came to a different conclusion that the underlying etiology is not relevant in determining the usefulness of DHC. Regardless of the etiology leading to intractable ICP, there is a final common pathway of decreased cerebral perfusion, which can lead to ischemia and further cerebral edema. This vicious cycle can perhaps be halted by the timely performance of DHC. Therefore, these conflicting findings could possibly be accounted for by the differences in the timing of DHC depending on the indication and underlying pathology. Early DHC versus delayed DHC was associated with improved functional outcome in several of these studies. 11, 13, 15 All of the studies reviewed found that DHC can be done safely in a population of patients with poor-grade SAH. Most of the studies suffer from the weaknesses inherent to a retrospective observational study and a very small sample size. Clearly, there is a need for prospective studies with standardized treatment protocols and clear indications for DHC in SAH.
Decompressive Hemicraniectomy in the Setting of Malignant MCA Infarct
Malignant middle cerebral artery infarct is described as a total or near total infarction of the MCA territory. 16 Due to the large area of ischemia, this injury is followed by massive amounts of cerebral edema, 17 peaking between days 2 and 5. 18 This progressive edema leads to herniation, resulting in death in approximately 80% of patients, even with the use of maximum medical therapy. 16, 19 Patients who survive are typically left severely disabled.
The guidelines by the AHA acknowledge the lack of evidence for conservative medical management in the treatment of patients with elevated ICP following stroke. 18 There is poor evidence for the benefit of hyperventilation, corticosteroids, or osmotic diuretics in improving functional outcome. It is currently a Class I recommendation that patients should be monitored closely for increased ICP. Currently, guidelines of the AHA and ASA state that osmotic therapy for patients with deterioration concerning for swelling is reasonable but do not recommend hypothermia, barbiturates, or steroids given insufficient data. They also state a Class I recommendation for DHC in patients younger than 60 years within 48 hours. 20 The Neurocritical Care Society (NCS) has similar recommendations against steroids and barbiturates but states that hypothermia may be considered in patients who are not eligible for surgery. They share the recommendation for osmotic therapy. In regard to surgery, the NCS also recommends DHC within 24 to 48 hours, regardless of age. However, an additional recommendation is made that families of patients older than 60 years should consider the higher likelihood of severe disability. 21 In recent years, there have been a number of randomized controlled trials comparing mortality and functional outcome between patients undergoing DHC and patients managed with maximum medical therapy. These studies have attempted to prove not just a mortality benefit of decompression but also an improvement in functional outcome. Table 3 provides a summary of the key studies that have been published thus far.
The Jüttler et al 23 (DESTINY) published a trial evaluating 32 patients ranging in ages from 18 to 60 years with symptom onset less than 36 hours prior to randomization and used a primary outcome of an mRS score 0 to 3 versus 4 to 6. The study was based on a sequential design, first evaluating 30-day mortality, and the study discontinued enrollment after 32 patients had undergone randomization and the mortality end point was reached. The conservative therapy group had a higher median National Institutes of Health Stroke Scale (NIHSS) of 24 when compared to the DHC group whose median NIHSS was 21. Survival was significantly higher in the surgical group compared to the conservative therapy group at 12 months. DESTINY was limited by its small patient size in part because the trial was terminated early given the immense survival benefit of the procedure and in light of the simultaneously conducted trials that will be discussed below. Although the article failed to reach its primary outcome, survival benefit was decisively shown.
Vahedi et al 22 (DECIMAL) studied 38 patients aged 18 to 55 years who were randomized within 24 hours of symptom onset. Patients randomized to DHC were required to undergo the procedure within 6 hours of randomization, at most 30 hours after symptom onset. Similar to DESTINY, the primary outcome was a favorable functional outcome (mRS 3) at 6 months. Under the guidance of the Data Safety Monitoring Committee, enrollment was suspended early at 38 patients (18 medical and 20 surgical) due to slow patient enrollment and the intention of DECIMAL, DESTINY, and HAMLET to pool data and publish together. Again, the primary outcome of mRS 3 did not reach statistical significance.
The third European randomized controlled trial (HAMLET) was conducted by Hofmeijer et al. 24 This study reported 64 patients randomized equally between surgical and medical management. One notable difference about HAMLET is that this study randomized patients up to 4 days after initial symptom onset. The primary outcome was mRS at 1 year, with a good outcome defined as 0 to 3 and poor outcome of 4 to 6. Recruitment was stopped under the advisement of the data monitoring committee after 64 patients were enrolled because it was thought to be very unlikely that the primary outcome measure would produce a statistically significant difference. Like DECIMAL and DESTINY, HAMLET did not show a statistically significant difference between an mRS of 0 to 3 versus 4 to 6. HAMLET, unlike DESTINY and DECIMAL, did not show a significant difference when outcome was dichotomized for mRS 4 (P ¼ .13).
With DESTINY, DECIMAL, and HAMLET recruiting patients simultaneously, the authors from each of these studies contributed data to an article by Vahedi et al. 27 This article pooled the data of the first 3 European trials to include patients randomized within 48 hours of symptoms onset. The article reported the data of 93 patients aged 18 to 60 years. All of the patients from DESTINY and DECIMAL were included, and 23 patients from HAMLET were included. Overall, 51 patients received decompressive surgery, whereas 42 received conservative therapy. Like each of the individual studies, there was a significant benefit for mRS > 4 cutoff and mortality at 1 year. Additionally, with the pooled data, there was a statistically significant difference between the groups for an mRS > 3 at 12 months (medical patients 79%, surgical patients 57%, P ¼ .014). This study also reported that the likelihood of ending up with an mRS of 4 was 10 times greater after surgery than after standard medical therapy, but the risk of ending up with an mRS of 5 was not increased.
Studies then began to consider the benefits of this procedure in an older population. Zhao et al 25 had a similar study design This was time to randomization; time to surgery is not reported.
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Journal of Intensive Care Medicine 31 (9) to the European trials but allowed patients to enroll up to 80 years of age. In patients older than 60 years, risk of death was also significantly lower at 1 year. There was no statistical difference between the groups for an mRS > 3. However, in the older subgroup, there was still a statistically significant difference when dichotomizing the groups to an mRS > 4, similar to the results with a younger patient population. The DESTINY group conducted a second randomized controlled trial further evaluating the effect of DHC on older patients. 26, 28 Unlike the pooled analysis of the European trials, the older patient population was not able to achieve statistical significance when the data were dichotomized to an mRS of 0 to 3 versus 4 to 6. DESTINY II showed a survival benefit and functional benefit with data dichotomized to an mRS 4, although the treatment effect was diminished in the older population.
Frank et al published Hemicraniectomy and durotomy upon deterioration from infarction related swelling trial (HeAD-DFIRST), 29 which randomized 26 patients within 96 hours after symptom onset. At 6 months, the DHC group and the medical group had a mortality rate of 36% and 40%, respectively, which was not consistent with the previous trials. However, the randomization for HeADDFIRST required more mass effect and allowed greater delay to randomization, which the authors speculated could have led to worse outcomes. Small enrollment numbers were another methodological limitation in this study.
This discussion focuses on the major randomized controlled trials evaluating DHC in the management of malignant MCA infarction. Mortality benefit is significant in all studies but HeADDFIRST. The pooled European trials were also able to show a functional benefit of surgery with an mRS of 0 to 3 compared to 4 to 6, although it also showed the increased risk of developing an mRS of 4. Whether this represents an acceptable outcome is a matter of debate and must be individualized for the patient. Even physicians have not come to a consensus as to the definition of an acceptable outcome (Neugebauer et al), although Kiphuth et al did find that most patients or their families would still retrospectively consent following decompression. 30, 31 These functional benefits were not reproducible using an older population, although mortality benefit and benefit with data dichotomized with an mRS 4 remained significant. Although more data regarding QoL and depression following DHC for malignant MCA stroke would be helpful in determining the utility of this life-saving procedure, a clear functional and mortality benefit has been established by the studies discussed above. In patients younger than 60 years who had large MCA infarcts, DHC is now strongly recommended as a treatment option. In patients older than 60 years, in whom a functional benefit has not yet been shown, DHC should be approached more cautiously as the benefit appears to be less in this age-group.
Decompressive Hemicraniectomy in the Setting of TBI
Traumatic brain injury is an extremely prevalent problem in the United States. Approximately 2 million people each year sustain TBI, many of whom can be treated and released from emergency departments. However, for the nearly 300 000 patients hospitalized each year, those with severe disease can have devastating outcomes, leading to thousands of deaths and patients with permanent disability. 32 The reported overall mortality with medical management varies widely throughout the literature but ranges approximately 30% to 40%. 33 Evaluation of hemicraniectomy in nonpenetrating diffuse TBI represents a more difficult analysis than surgery following malignant MCA infarct. The initial injury prompting evaluation for surgery has more variability. The decompressions themselves can be pursued for different purposes, aiming to treat primary damage caused by lesions, causing mass effect or secondary damage caused by elevated intracranial pressure. 34, 35 Additionally, the preferred surgical approach and timing 35 of the surgery is still unclear. The pivotal study Decompressive craniectomy in diffuse traumatic brain injury (DECRA) used a bifrontal approach to their craniectomy. 36, 37 Other studies used a bilateral hemicraniectomy approach. 38 As we are limiting our discussion to unilateral DHC, a bifrontal decompression and bilateral DHC fall outside the scope of this review. The literature available is therefore limited due to the variability of the initial injury as well as the surgical approach employed.
To our knowledge, only 2 published randomized controlled trials compare decompressive craniectomy in TBI compared to maximum medical management: DECRA evaluated a bifrontal approach and yielded disappointing results, 36 and a small study evaluating decompression in children showed a possible benefit. 39 DECRA randomized 155 patients with severe TBI to a bifrontal decompressive surgical arm versus medical management arm. Although surgical patients spent fewer days in intensive care, there was no difference in mortality between the groups, and the surgical arm had worse Extended GOSs than those receiving medical management. A third randomized controlled trial, Randomized Evaluation of Surgery with Craniectomy for Uncontrolled Elevation of intracranial pressure (RescueICP), has yet to be published and will evaluate bifrontal and unilateral hemicraniectomies. 40 With so few randomized controlled trials, the optimal surgical approach remains controversial for TBI.
Current guidelines for controlling ICP in TBI remain focused on conservative management as first-line therapies: elevation of the head of the bed, pain control, sedation, and ventriculostomy. When this fails to acutely manage ICP, barbiturate, hypothermia, and hyperosmolar therapies have been used. 41 Outcomes of patients with severe TBI managed with maximum medical therapy vary in the literature but frequently show a mortality rate of around 40% and rates of good outcome (Glasgow Outcome Score 4-5) of 40%. 42 Decompressive hemicraniectomy is considered when these therapies fail and ICP remains elevated. Decompressive hemicraniectomy can rapidly decrease ICP, however, the clinical significance and outcome benefit remain unclear. 41 Wen et al 35 compared early versus late DHC, defining early DHC as within 24 hours of injury in 44 patients with TBI. Both groups had a 6-month mortality rate of approximately 20%. However, 52% in the early DHC group achieved a GOS of 4 to 5, compared to 63% in the late group, which did not reach statistical significance. Although the groups were similar, the early group had a more significant midline shift. It is possible that the treatment effect is too small to be detected with such a small sample size.
Aside from the study of early versus late DHC in patients with TBI, there is controversy regarding whether decompression with or without evacuation of a mass lesion is more efficacious. Yuan et al 43 studied this question by examining 164 patients, 93 of whom underwent decompression with evacuation of a mass lesion at least 25 mL and 71 who were decompressed without evacuation of a mass lesion. About 15% more patients from the mass lesion group underwent surgery within 24 hours (72% mass lesion, 58% diffuse edema). The mortality rate was 22% at 60 days and favored the mass lesion group (14% mass lesion, 32% diffuse edema; P ¼ .014). The overall rate of good outcome was about 42% without a statistically significance difference between the 2 groups.
Aarabi et al 44 performed a similar retrospective cohort study to evaluate 50 patients with severe closed TBI but excluded patients who had DHC with evacuation of a mass lesion. Ten patients underwent surgery within the first 24 hours (9 immediately and 1 secondary to clinical worsening). The remaining 40 patients underwent DHC after 24 hours. The overall mortality was 28%, and 51% of the patients had a good outcome with GOS 4 to 5 at 30 days. The remaining patients were left vegetative or severely disabled. One limitation of this study is that surgical patients were selected of 967 patients with TBI based on an inability to control ICPs with medical management, thus the surgical population had already failed medical therapy.
Qiu et al 45 evaluated 74 patients with brain swelling after severe TBI and randomized patients to undergo a traditional DHC (bone window diameter 15 cm) compared to the control group that underwent a unilateral temporoparietal craniectomy (bone window diameter 8 cm). Thirty-seven patients underwent a DHC, and 57% of these patients had a GOS of 4 to 5 at 6 months. Additionally, 27% of the patients died, and the remaining were vegetative or severely disabled. The control group had a 57% mortality rate with only 33% achieving a good outcome. Jiang et al 46 conducted a similar study that included 486 patients. The results were similar favoring the group who underwent a traditional DHC versus a subtotal DHC.
Some of the most relevant data is from Chibbaro et al. 47 This prospective study of 147 patients evaluated DHC following TBI. Of these patients, 67% had a GOS 4 to 5 at a mean follow-up of 26 months. Glasgow Outcome Scale was 2 to 3 in 19% of patients, and mortality rate was just 14%. Subgroup analysis was performed to determine factors associated with improved outcome. Good outcomes were significantly associated with age less than 50 years (P < .0001) and operation within 9 hours of trauma (P < .03). Selection bias limited this study. Patients with midbrain or pons hemorrhages on initial computed tomography were excluded.
Throughout the literature, good outcome rates vary from 30% to 50% in the DHC group, with a mortality rate approximately 20%, 48, 49 although these numbers remain heterogeneous in the literature. Decompressive hemicraniectomy remains a controversial option in the management of patients following TBI. Studies in the form of randomized controlled trials comparing DHC to maximal medical management are needed to further investigate whether decompression in TBI improves mortality and how timing may impact its utility. Unfortunately, there remain a number of barriers to studies of this kind. The heterogeneity of patients with TBI will be a constant challenge. Mechanism of injury, the presence or absence of a mass lesion, and the possible presence of other injury remain challenges for patient randomization and data interpretation. Additionally, researchers continue to disagree about the surgery's timing (early vs late), use for mass lesions versus diffuse edema, and even the preferred surgical approach.
Complications
One must be aware that the performance of DHC is associated with some risk, and some of the most common complications of this procedure will be briefly discussed. Hemorrhage broadly defined as new bleeding near or remote from the surgical approach, extension of a prior bleed, or hemorrhagic conversion of ischemic stroke occurs in about 12% of patients after DHC. 50 This risk is higher in patients with DHC for ischemic stroke (20.7%). Cerebrospinal fluid (CSF) abnormalities following DHC are also common, occurring in 18% of all patients. One of the most common examples of this complication is the development of a subdural hygroma occurring in as many as 27% of patients with TBI. 50 The presence of a subdural hygroma is associated with worse functional outcome and a longer hospital stay. Other CSF abnormalities that may occur are hydrocephalus and a CSF leak. These complications may require an additional intervention or procedure. Poor wound healing or wound infection occurs in 8% of patients. A rare but important complication to be aware of is the development of the ''syndrome of the trephined'' also known as ''sinking skin flap syndrome.'' This syndrome can lead to paradoxical herniation, and the only known definitive treatment is replacement of the bone via cranioplasty. Lastly, all patients require a second surgery for cranioplasty that carries its own inherent risks, although the overall complication rate of cranioplasty is less than that of DHC (6.4% vs 13.4%). 50 
Conclusions
In this review, we describe the current evidence regarding the utility of DHC for the management of elevated ICP due to malignant MCA stroke, ICH, TBI, and SAH. All of these disease processes share a common pathophysiologic end point of elevated ICP that can be refractory to maximal medical therapy and lead to herniation syndromes. It appears that DHC can be safely performed with minimal risk in these critically ill patients. Furthermore, it appears that the earlier DHC is performed, the greater the potential benefit. Although DHC may be a life-saving procedure, the patients are nevertheless often left significantly impaired. Therefore, it is imperative to discuss the potential outcomes that are possible with the patient or surrogate decision maker. The issue of prognostication of outcome in severe brain injury is beyond the scope of this article, but it is clear in all of the disease processes reviewed that a potential exists for a good functional recovery. Therefore, DHC should be part of the armamentarium in the management of elevated ICP in the conditions discussed. Ultimately, the decision to pursue DHC should be individualized taking into consideration the patient's values and goals of care.
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